MAPT and Alzheimer disease: Elevated levels of this protein were reported in the AD brain [174], CSF [175], and the ICV animal model of AD [176], which conceivably could lead to altered binding to two of its normal binding partners, i.e., glycogen synthase kinase-3β (GSK3β) and tau, and may promote tau phosphorylation and polymerization, potentially to the formation of NFT.